Participation of the Czech population in the Colorectal Cancer Screening Programme – trends and current situation

Česká verzia

Authors: O. Ngo ^1,2; B. Bučková ^1,2; Š. Suchánek ³; B. Seifert ⁴; M. Zavoral ³; L. Dušek ^1,2; O. Májek ^1,2
Authors place of work: Ústav zdravotnických informací a statistiky České republiky, Praha ¹; Institut biostatistiky a analýz, LF MU, Brno ²; Interní klinika 1. LF UK a ÚVN – VFN Praha ³; Ústav všeobecného lékařství, 1. LF UK v Praze ⁴
Published in the journal: Gastroent Hepatol 2017; 71(5): 377-383
Category: Gastrointestinal Oncology: Review Article
doi: https://doi.org/10.14735/amgh2017377

Summary

Background:
The Czech Republic has a leading position in colorectal cancer incidence and mortality in comparison with other countries. The screening programme, which has been implemented in the Czech Republic since 2000, is an essential part of prevention. The success of the programme depends on the participation of the target population. Many activities have been carried out to promote a higher adherence of the population to screening. At the beginning of 2014, the programme was strengthened by introducing personalised invitations to screening for non-attenders. The aim of the paper is to present the current situation in terms of coverage of the target population by screening examinations and the participation rate after personalised invitations in the Czech Republic.

Material and Methods:
Data from healthcare payers, which capture a fully representative profile of all screening tests provided at the national level, were used to evaluate the coverage of the target population (up to 2016) and the participation rate after invitation (for invitations sent from January 2014 to December 2016).

Results:
Coverage of the target population has been growing for many years. A significant increase occurred in 2010 after a change in the programme setting and another in 2014 after the introduction of personalised invitations. The coverage was growing up to 2015 (32.2%), but the following year saw the first decline in the history of the screening programme (by more than 2%). During the first 3 years of the project of personalised invitations, over 3.7 million invitations were sent (2 million first invitations, 1 million second invitations and 666,000 third invitations). Participation rates were 20.9% after the first invitation, 18.9% after the second invitation and 11.5% after the third invitation.

Conclusion:
The coverage by screening in the Czech Republic has not yet reached the internationally recommended level of 45%. In addition, a large proportion of the population do not respond to repeated invitations to screening. It is necessary to continue setting up measures aimed at making the target population more interested in their participation in the screening programme.

Key words:
colorectal neoplasms – mass screening – personalised invitations – occult blood – screening coverage – participation rate

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
18.9.2017

Accepted:
4.10.2017

Zdroje

1. Ferlay J, Soerjomataram I, Dikshit R et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [online]. Available from: globocan.iarc.fr.

2. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Available from: www.svod.cz.

3. Kim PJ, Plescia J, Clevers H et al. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362 (9379): 205–209.

4. Stewart BW, Wild CP. World Cancer Report 2014. Lyon: International Agency for Research on Cancer 2014.

5. The council of the European union. Council Recommendation of 2 December 2003 on cancer screening. December 2003. [online]. Available from: http: //eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ: L: 2003: 327: 0034: 0038: EN: PDF.

6. Zavoral M, Suchanek S, Zavada F et al. Colorectal cancer screening in Europe. World J Gastroenterol 2009; 15 (47): 5907–5915.

7. Ponti A, Anttila A, Ronco G et al. Cancer screening in the European Union (2017). Report of the implementation of the Council Recommendation on cancer screening. 2017. France: International Agency for Research on Cancer 2017.

8. Suchanek S, Majek O, Vojtechova G et al. Colorectal cancer prevention in the Czech Republic: time trends in perfor-mance indicators and current situation after 10 years of screening. Eur J Cancer Prev 2014; 23 (1): 18–26. doi: 10.1097/CEJ. 0b013e328364f203.

9. van Rossum LG, van Rijn AF, Laheij RJ et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135 (1): 82–90. doi: 10.1053/j.gastro.2008.03.040.

10. Grega T, Májek O, Ngo O et al. Současné principy screeningu kolorektálního karcinomu – od oportunního k populačnímu screeningovému programu. Gastroent Hepatol 2016; 70 (5): 383–392. doi: 10.14735/amgh2016383.

11. Zavoral M, Vojtěchová G, Májek O et al. Population colorectal cancer screening in the Czech Republic. Cas Lek Cesk 2016; 155 (1): 7–12.

12. Dušek L, Májek O, Blaha M et al. Koncepce populačního screeningu v České republice, metodika a první výsledky adresného zvaní občanů do preventivních onkologických programů. Klin Onkol 2014; 27 (Suppl 2): 2S59–2S68. doi: 10.14735/amko20142S59.

13. Segnan N, Patnick J, von Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. 1st ed. Luxembourg: Publications Office ot the European Union 2010.

14. OECD. Survival and mortality for colorectal cancer. Health at a Glance 2015: 154–155.

15. Dušek L, Májek O, Mužík J et al. Epidemiologie a populační screening nádorů tlustého střeva a konečníku v ČR na podkladě nově dostupných dat. Gastroent Hepatol 2015; 69 (6): 509–517. doi: 10.14735/amgh2015509.

16. Malila N, Oivanen T, Malminiemi O et al. Test, episode, and programme sensitivities of screening for colorectal cancer as a public health policy in Finland: experimental design. Br Med J 2008; 337: a2261. doi: 10.1136/bmj.a2261.

17. Zavoral M, Suchanek S, Majek O et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014; 20 (14): 3825–3834. doi: 10.3748/wjg.v20.i14.3825.